Advanced ampullary cancer: post-hoc analysis of the ABC-01, ABC-02, and ABC-03 clinical trials
Open Access
- 14 December 2025
- journal article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (2)
Abstract
Ampullary carcinoma (AC) is a rare malignancy. It is often classified within biliary tract cancers (BTC) but lacks dedicated treatment guidelines. This post-hoc analysis evaluated outcomes of patients with advanced AC enrolled in the ABC-01, ABC-02, and ABC-03 clinical trials to provide reference data for future studies. All patients with advanced AC formed the “Descriptive cohort,” while those AC treated with cisplatin–gemcitabine (CisGem) comprised the “CisGem-treated cohort.” Among 534 trial participants, 28 (5.24%) had AC, and 17 received CisGem. The median age was 63.93 years, and 75.00% were male. Most patients had metastatic disease at baseline (89.29%). Median follow-up for the CisGem-treated cohort was 10.23 months (95% CI 5.98-14.43). The objective response rate was 23.52%, and disease control was achieved in 58.82% of patients. Estimated median progression-free survival (PFS) and overall survival (OS) were 7.98 months (95% CI, 6.86-8.44) and 11.76 months (95% CI, 5.94-14.88), respectively, comparable to outcomes in other BTCs. No reliable prognostic or predictive factors for PFS, OS, or ORR were identified, likely reflecting the small sample size. This analysis underscores the rarity of advanced AC and the challenges in recruiting adequate numbers for dedicated trials. While CisGem remains an appropriate standard-of-care regimen, modest survival outcomes highlight the need for improved therapies. Molecular profiling has revealed potentially actionable alterations, including HER2 amplification and KRAS mutations, supporting precision oncology approaches. This study provides the most comprehensive reference dataset to date for advanced AC treated with CisGem and emphasizes the importance of international collaboration and molecularly guided research to improve outcomes in this rare malignancy.Keywords
This publication has 17 references indexed in Scilit:
- 323P Early safety and efficacy from the phase IIIb TOURMALINE study of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in advanced biliary tract cancer (aBTC)Annals of Oncology, 2025
- A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancerJournal of Hepatology, 2025
- ESMO Clinical Practice Guideline interim update on the management of biliary tract cancerESMO Open, 2024
- 94MO Advanced extrahepatic cholangiocarcinoma: Post-hoc analysis of the ABC-01, -02 and -03 clinical trialsAnnals of Oncology, 2023
- Elevated CA 19-9 is associated with worse survival in patients with resected ampullary adenocarcinomaSurgical Oncology, 2023
- Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2023
- The pathohistological subtype strongly predicts survival in patients with ampullary carcinomaScientific Reports, 2019
- Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trialThe Lancet Oncology, 2015
- Clinical significance of pathologic subtype in curatively resected ampulla of vater cancerJournal of Surgical Oncology, 2011
- Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 StudyBritish Journal of Cancer, 2009